Ligand Pharmaceuticals (NASDAQ:LGND) is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The company's portfolio is diverse, covering areas such as gene therapy, oncology, antivirals, neuroscience, and immune disorders among others. Ligand's business model is based on leveraging its proprietary drug discovery technologies, including its patented Ph.D. (Phage Display) libraries, OmniAb® animal platforms for antibody discovery, and LTP (Liver Targeting Prodrug) technology, to partner with or license to other pharmaceutical companies. These collaborations are designed to generate recurring revenue streams through royalties, milestones, and licensing fees. The company's objective is to continue expanding its technology portfolio, thereby increasing its partnerships and licensing agreements, to ultimately improve patient care by aiding in the discovery and development of novel therapeutics.